Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Giuseppe Procopio,Michele Prisciandaro,Roberto Iacovelli,Enrico Cortesi,Giuseppe Fornarini,Gaetano Facchini,Giacomo Cartenì,Roberto Sabbatini,Gabriella Del Bene,Luca Galli,Claudia Caserta,Andrea Giovanni Multari,Marco Bregni,Francesco Massari,Sebastiano Buti,Ugo De Giorgi,Fable Zustovich,Michele Milella,Fabio Calabrò,Maria Laura Mancini,Giampaolo Tortora,Claudio Vernieri,Daniele Santini,Mariella Sorarù,Riccardo Ricotta,Cristina Masini,Marcello Tucci,Stefano Luzi Fedeli,Cinzia Ortega,Antonella Mecozzi,Raffaele Ratta,Cora N Sternberg,Elena Verzoni Clinical Genitourinary Cancer（2018）
摘要
Cabozantinib showed acceptable tolerability and activity in a large unselected population treated according to everyday clinical practice.
更多查看译文
关键词
c-Met,Metastatic renal cell carcinoma,METEOR study,Targeted therapy,VEGF inhibitor
AI 理解论文
溯源树
样例
